Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Imprimis Pharmaceuticals, Inc.
(OP:
IMMY
)
1.600
USD
UNCHANGED
Last Price
/ Updated:
8:10 PM EST, Feb 7, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
1.600
Today's Range
1.600 - 1.600
52wk Range
0.5100 - 6.000
Shares Outstanding
N/A
Dividend Yield
N/A
Top News
More News
Imprimis Pharmaceuticals Prices 1.84M Share Offering at $5.25/Share
February 07, 2013
Imprimis Pharmaceuticals (NASDAQ: IMMY ), today announced the pricing of an underwritten public offering of 1,840,000 shares of its common stock at a price to the public of $5.25 per share, for gross...
Read More
category
Management
,
Benzinga
,
IMMY
, and 2 more.
from
Latest Articles from Benzinga.com
Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
February 07, 2013
Closing of Offering Expected February 13, 2013
Read More
from
PR Newswire
More News
Read More
Gus Bassani Joins Imprimis Board Of Directors
December 18, 2012
from
PR Newswire
Imprimis to Begin New Study of Its Topical Analgesic Drug
September 19, 2012
from
PR Newswire
Imprimis Names Two Experts To Its Science And Regulatory Board
September 12, 2012
from
PR Newswire
Strategic Agreement Launches Novel Drug Development Model
September 07, 2012
from
PR Newswire
Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
August 20, 2012
from
PR Newswire
Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
August 07, 2012
from
PR Newswire
Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
July 27, 2012
from
PR Newswire
MDB Capital Group Showcases Leading Disruptive Technology Companies at Bright Lights 2012 Conference in New York
July 18, 2012
from
Marketwired News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here